Helix BioPharma to Present Clinical Progress and NASDAQ Uplisting Plans at Q3 Investor Summit

Helix BioPharma Corp. will present at the Q3 2025 Investor Summit Virtual on September 16, 2025, focusing on its clinical development pipeline and strategic corporate milestones. The company, a clinical-stage oncology firm, will detail preparations for a Phase Ib/Randomized Phase II study of L-DOS47 combined with pembrolizumab for first-line non-small cell lung cancer (NSCLC) treatment. This combination therapy aims to enhance the effectiveness of existing anti-cancer treatments by targeting CEACAM6-expressing tumors, potentially improving outcomes for patients with this challenging cancer type.

Additionally, Helix plans to discuss its anticipated uplisting to NASDAQ in Q1 2026, a move intended to increase visibility and access to global capital markets. These initiatives reflect the company's broader strategy to accelerate oncology asset development and transform hard-to-treat cancers into manageable conditions. Investors attending the virtual event can register for free at https://investorsummitgroup.fillout.com/t/8CZGk3gSQbus to gain insights directly from CEO Thomas Mehrling, MD, PhD, during one-on-one meetings.

The Investor Summit, organized by Investor Summit Group, serves as a platform for connecting undervalued microcap companies with institutional investors and high-net-worth individuals. Helix's presentation, scheduled for September 16 at 2:30 PM ET, will be accessible via webcast at https://investorsummitgroup.com/presentor/q3-track-1-helix-biopharma-corp/. This event emphasizes companies with strong growth catalysts, aligning with Helix's ongoing clinical progress and corporate expansion efforts.

Helix's pipeline includes L-DOS47, an antibody-enzyme conjugate designed to sensitize tumors to therapy, alongside pre-IND candidates LEUMUNA™ for post-transplant leukemia relapse and GEMCEDA™, an oral gemcitabine prodrug. These developments could significantly impact oncology treatment paradigms, offering new options for patients with limited alternatives. The company's focus on near-term solutions for hard-to-treat cancers underscores the potential industry-wide implications of its research, potentially influencing future therapeutic approaches and investment in oncology innovation.